We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Obalon Therapeutics Inc | NASDAQ:OBLN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | 2.81 | 2.87 | 0 | 01:00:00 |
|
|
|
001-37897
|
|
20-1828101
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|||
Common stock, par value $0.001 per share
|
OBLN
|
The NASDAQ Stock Market LLC
(NASDAQ Global Market)
|
•
|
issued and sold $2.9 million in shares of its common stock in May 2019 and June 2019 pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC;
|
•
|
issued and sold $2.9 million in shares of its common stock in May 2019 and June 2019 pursuant to the Company’s equity distribution agreement with Canaccord Genuity LLC;
|
•
|
issued and sold $3.0 million in shares of its common stock to investors in a registered direct offering in May 2019; and
|
•
|
issued and sold shares of its common stock, pre-funded warrants and purchase warrants in August 2019 pursuant to a Registration Statement (No. 333-232276) on Form S-1 for net proceeds of approximately $15.4 million, after deducting underwriting discounts and commissions and expenses payable by the Company.
|
|
|
OBALON THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date: October 3, 2019
|
|
By:
|
/s/ William Plovanic
|
|
|
|
William Plovanic
|
|
|
|
President and Chief Financial Officer
|
1 Year Obalon Therapeutics Chart |
1 Month Obalon Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions